Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | ILK | Q13418 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049940 | 0.79 | ENPP1 (0.50) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL28050040 | 0.78 | MAPT (0.45) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL4512570 | 0.78 | KDR (0.57) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL4507968 | 0.78 | ACHE (0.46) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL1346309 | 0.78 | PDE4A (0.44) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL3424568 | 0.78 | PDE4A (0.44) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL4498760 | 0.77 | KDR (0.39) | KDRFGFR1FLT1ENPP1PDE4A | |
| Hydrochloric Acid SCHEMBL5566426 | 0.77 | KDR (0.56) | KDRFGFR1FLT1ENPP1PDE4A | |
| Benzene SCHEMBL28049942 | 0.77 | ENPP1 (0.55) | KDRFGFR1FLT1ENPP1PDE4A | |
| SCHEMBL30640012 | 0.76 | ENPP1 (0.55) | KDRFGFR1FLT1ENPP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | claimed |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| EP-1458394-B1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | GSK3A, GSK3B, PYGB | KDR 3980/4885FGFR1 3375/4885FLT1 3848/4885 |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | GSK3A, GSK3B, PSEN1 | KDR 3528/4885FGFR1 3328/4885FLT1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.